⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Table S3 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma

Patrick Schöffski Rastislav Bahleda Andrew J. Wagner Melissa Burgess Niels Junker Michael Chisamore Patrick Peterson Anna M. Szpurka Matteo Ceccarelli William D. Tap

View at Publisher

Ask AI

Bookmark

Share

Abstract

Table S3: Pharmacokinetic parameters after a 60-minute IV infusion of olaratumab on Day 1 and Day 8 of Cycle 1 and Cycle 3 with pembrolizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schöffski et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522b9d https://doi.org/10.1158/1078-0432.27032644.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S3 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024
2Table S4 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024
3Table S4 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024
4Table S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024
5Table S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024

More related papers

Data from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024
Figure S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024
Pembrolizumab and Sarcoma: A meta-analysis2025